The regulatory submission landscape in oncology
How submissions work — the clinical team's roleFoundation
A regulatory submission is not a document assembly exercise. It is a scientific argument made to a regulator — the argument that a drug's benefits outweigh its risks in a defined oncology population at a defined dose and schedule. The clinical team's role is to ensure that argument is complete, coherent, and clinically defensible.
Every submission type (IND, NDA, BLA) requires different content, different timelines, and different standards of evidence. In oncology specifically, submissions are reviewed by CDER (small molecules) or CBER (biologics) at FDA, with the Office of Oncology Products (OOP) playing a central coordinating role for both.
Every submission type (IND, NDA, BLA) requires different content, different timelines, and different standards of evidence. In oncology specifically, submissions are reviewed by CDER (small molecules) or CBER (biologics) at FDA, with the Office of Oncology Products (OOP) playing a central coordinating role for both.
Submission types — when each is usedFramework
IND (Investigational New Drug)Required before initiating any Phase 1 clinical trial in the US. The IND authorizes the sponsor to ship the investigational drug across state lines and to conduct clinical trials. Without an active IND in good standing, no US clinical trial can proceed. IND amendments are submitted for every major protocol change, new safety information, and annual safety reporting.
NDA (New Drug Application)Submitted for small molecule drugs (chemical entities). Requires complete clinical, nonclinical, and manufacturing data demonstrating safety and efficacy. In oncology, most NDAs are for targeted therapies, chemotherapy agents, and ADC payloads (small molecule component).
BLA (Biologics License Application)Submitted for biological products — monoclonal antibodies, checkpoint inhibitors, antibody-drug conjugates (the antibody component), cell and gene therapies, therapeutic proteins. Higher manufacturing complexity requirements than NDA. In oncology, the majority of new IO approvals are BLAs.
sNDA / sBLA (supplemental)Filed for new indications, new patient populations, new doses, or new formulations of already-approved drugs. In oncology, supplemental applications are extremely frequent as drugs gain approvals across multiple tumor types.
The oncology submission differenceWhy oncology is different
Oncology submissions differ from other therapeutic areas in several fundamental ways that the clinical team must understand:
Surrogate endpoints acceptedFDA accepts ORR, PFS, and DFS as primary endpoints for accelerated or regular approval in oncology, whereas most other therapeutic areas require mortality or irreversible morbidity endpoints. This reflects the unmet need and the difficulty of conducting OS-powered trials in all settings.
Single-arm trials acceptableAccelerated Approval in oncology frequently uses single-arm Phase 2 trials with ORR as the basis. No randomized control arm required if the response rate is considered highly unlikely to occur spontaneously. This is unique to oncology among most disease areas.
Biomarker-defined populationsOncology submissions increasingly define the approved population by a companion diagnostic biomarker (EGFR mutation, PD-L1 expression, MSI-H, TMB-H). The CDx must be co-submitted and co-approved. The clinical team must understand the biomarker strategy as part of the submission package.
Post-marketing confirmatory trialsAccelerated Approval grants initial approval based on surrogate endpoints, with a required post-marketing confirmatory trial demonstrating clinical benefit. The clinical team must understand the confirmatory trial obligations at the time of submission — they are legally binding commitments.
Initial IND — content and clinical reviewPhase 1 authorization
The initial IND is FDA's first formal review of the sponsor's plan to study the drug in humans. FDA has 30 days to review and either allow the IND to proceed or place it on clinical hold. The clinical team must ensure the IND makes a scientifically credible case for why the proposed Phase 1 study can be conducted safely.
Investigator's Brochure (IB)The IB is the central clinical document in every IND. It summarizes all preclinical and clinical data available at the time of filing. In an initial IND for a new oncology drug, this is primarily preclinical — toxicology, pharmacology, PK, mechanism of action. The clinical team reviews for: is the proposed starting dose supported by the preclinical data? Is the dose escalation scheme scientifically justified?
Protocol (Phase 1)The Phase 1 protocol defines the starting dose (typically 1/10th of the NOAEL in the most sensitive species, or 1/6th of the HNSTD for biologics), the escalation schema (3+3, BOIN, mTPI-2, i3+3 — the clinical team must understand the chosen design), dose-limiting toxicity (DLT) definition, and stopping rules. Every DLT criterion in the protocol has a direct bearing on what gets reported as a DLT in the safety section.
Informed consentThe Phase 1 consent form for a first-in-human oncology study must clearly communicate: the investigational nature of the drug, all known risks from preclinical studies translated to human terms, that the primary goal is safety not treatment, and the alternative treatments available. The clinical team reviews for scientific accuracy and regulatory completeness.
30-day review clockFDA has 30 days from IND receipt to place a clinical hold or allow the study to proceed. If no clinical hold is issued by day 30, the IND is considered in effect. The clinical team must be available to respond to any FDA questions during this window — typically called an "IND Day 30 response" if FDA has queries.
IND amendments — what requires a submissionProtocol changes
Protocol amendmentRequired for any major protocol change: new dose levels, new patient population, new eligibility criteria, new endpoints, new safety monitoring rules. Must be submitted before the change is implemented. Minor administrative changes may be filed as information amendments without requiring pre-approval.
New investigator (Form FDA 1572)Every new clinical site added to the IND requires a Form FDA 1572 from the principal investigator. The 1572 is a legal commitment — the PI certifies they will conduct the trial per protocol and GCP. The clinical team must verify 1572 completeness before allowing a new site to enroll patients.
IB updateThe IB must be updated when new significant safety or efficacy information becomes available. In an oncology program running multiple trials simultaneously, the IB is often updated annually. Major new safety signals (new SAE type, Hy's Law case, unexpected cardiac signal) trigger an urgent IB update and distribution to all active investigators.
Response to clinical holdIf FDA places the IND on clinical hold (stopping enrollment), the sponsor must respond to every FDA concern in writing. The clinical team prepares the clinical response — addressing each concern with data and a proposed resolution. FDA has 30 days to review the clinical hold response.
IND safety reporting — timelines and obligationsRegulatory obligation
7-day expedited reportRequired for: unexpected fatal or life-threatening suspected adverse reaction (SUSAR). Clock starts from when the sponsor first receives information suggesting the event may be related to the study drug. Cannot wait for full investigation — initial report filed within 7 days, follow-up with complete information within 15 days.
15-day expedited reportRequired for: any other unexpected serious suspected adverse reaction (serious but not fatal/life-threatening). "Unexpected" means not listed in the IB or not listed at the observed frequency/severity. In oncology, where many serious AEs are expected (neutropenia, anemia), the "unexpected" determination is a critical medical judgment.
Expectedness assessmentThe clinical team determines whether each SAE is "expected" (listed in the IB with the observed characteristics) or "unexpected." Expected SAEs do not trigger expedited reports — they are reported in the annual IND report. The IB must be current and specific enough to make this determination credible. A vague IB listing creates a gray zone that defaults to "unexpected" and triggers reporting obligations.
Aggregate safety reportsWhen multiple cases of the same SAE type accumulate (e.g., 3 cases of grade 4 ALT elevation), this may constitute an aggregate safety signal even if each individual case was expected. The clinical team must conduct periodic aggregate safety analysis — not just case-by-case review.
FDA 21 CFR 312.32 is the governing regulation. IND safety reporting violations are among the most cited GCP deficiencies in FDA inspections. The clinical team must have a written process for safety report triage, timing, and escalation — and it must be followed consistently.
Annual IND report — clinical review contentYearly obligation
Due within 60 days of the IND anniversary date. The annual report is FDA's primary tool for ongoing oversight of the program between submissions. The clinical section must include:
- Summary of all studies conducted under the IND during the past year — status, enrollment, key findings
- Summary of all IND safety reports submitted during the year — number, type, and key patterns
- Aggregate safety analysis — all serious AEs by system organ class, with comparison to IB expectations
- Updated IB if significant new safety or efficacy information has emerged
- Protocol status — active protocols, protocols placed on hold, protocols completed
- General investigational plan for the coming year — planned new protocols, new indications, new populations
- Phase 1 data summary — DLT rate, MTD or RP2D determination if reached, preliminary PK/PD data
NDA CTD structure — eCTD formatSmall molecule oncology
NDAs are submitted in the Common Technical Document (CTD) format, organized into 5 modules. Oncology NDAs are reviewed by CDER's Office of Oncology Products.
Module 1 — AdministrativeCover letter, form FDA 356h, proposed prescribing information (labeling), patent certifications, regulatory correspondence. The clinical team reviews the proposed labeling — this is the most important document in the NDA from a clinical standpoint.
Module 2 — SummariesClinical Overview (2.5) and Clinical Summary (2.7) are the primary clinical review documents. The clinical team writes these. The Clinical Overview is a critical synthesis of the benefit-risk argument — typically 30–50 pages. The Clinical Summary is a detailed statistical and clinical analysis — typically 300–500 pages.
Module 3 — Quality (CMC)Drug substance and drug product manufacturing, characterization, stability. The clinical team reviews for consistency between the clinical formulation used in trials and the proposed commercial formulation.
Module 4 — NonclinicalPharmacology, toxicology, ADME studies. The clinical team uses Module 4 data to contextualize clinical findings — especially for unexpected AEs where mechanism understanding requires preclinical correlation.
Module 5 — ClinicalAll clinical study reports (CSRs), individual patient data listings, and integrated analyses. The full T&L package lives here. This is typically the largest module — oncology NDAs often have Module 5 packages of 100,000+ pages.
Clinical sections the team must review and ownClinical ownership
Clinical Overview (2.5)The most important single document in the NDA. It is the sponsor's integrated benefit-risk argument. Structure: background and rationale, overview of clinical pharmacology, overview of efficacy, overview of safety, benefit-risk conclusions. The FDA reviewer reads this first. It must be a coherent scientific argument, not a summary of summaries.
Integrated Summary of Safety (ISS)Pools safety data across all studies in the development program. The clinical team reviews for: consistency of AE rates across studies, dose-toxicity relationships, subgroup safety differences (organ impairment, age, sex, race, prior therapy). In oncology, the ISS must specifically address Hy's Law analysis across the integrated dataset.
Integrated Summary of Efficacy (ISE)Pools efficacy data across all studies. In oncology, typically one pivotal trial drives the primary efficacy claim, with supportive studies providing context. The ISE must address: primary endpoint results, confirmatory evidence from supportive studies, subgroup analyses, and relationship between efficacy and biomarker status.
Individual CSRs (Module 5)Each clinical study has a full CSR per ICH E3 structure. The clinical team reviews every CSR for the pivotal trial(s) in detail — Section 12 (efficacy) and Section 12.4 (safety). Supporting study CSRs are reviewed at the section level with focus on any safety signals not seen in the pivotal trial.
The benefit-risk framework: FDA uses a structured benefit-risk framework (PDFR: Population, Disease severity, Factors that affect the framework, Risks, Benefits) to evaluate every NDA. The clinical team must anticipate how FDA will apply this framework and ensure the Clinical Overview addresses each dimension explicitly.
Integrated safety — oncology-specific requirementsSafety package
Safety population definitionAll patients who received at least one dose of the study drug. This is the denominator for all safety analyses. The ISS must clearly define this population and account for all patients who were enrolled but did not receive treatment — these are not in the safety population and must be explained.
Deaths analysisAll deaths must be accounted for: on-treatment deaths, deaths within 30 days of last dose, and deaths after 30 days with an AE that started on treatment. A death narrative listing must be included. FDA specifically looks at the proportion of deaths attributed to study drug toxicity vs disease progression — and whether that attribution is clinically defensible.
Hepatic safety (Hy's Law)Mandatory for every NDA. The integrated Hy's Law analysis must pool data across all studies and present: ALT/AST shift tables, Hy's Law scatter plot with all patients, individual narratives for all cases in the upper-right quadrant, and Temple's Corollary documentation. FDA will query any NDA that does not include this analysis.
Cardiac safety (QT analysis)A formal thorough QT study (TQT) or a population PK-QT analysis is required for most small molecule NDA submissions. The clinical team reviews the QT analysis for: QTcF mean and maximum changes, relationship between drug exposure and QTc prolongation, proportion of patients above 450, 480, 500ms thresholds.
Special population safetyHepatic impairment, renal impairment, elderly patients (≥65 years), pediatric patients if applicable. Labeling dose recommendations for special populations must be supported by either dedicated PK studies or population PK modeling with clinical validation. Missing special population data generates FDA label restrictions.
Proposed labeling — the clinical team's most important outputLabeling strategy
The prescribing information (PI) is the legally binding document that defines how the drug will be used. Every claim in the PI must be supported by data in the NDA. The clinical team is responsible for the clinical sections of the proposed PI.
Indications and UsageThe most contested section in any oncology submission. Defines the exact patient population (tumor type, histology, biomarker status, prior therapy, line of therapy). FDA will negotiate this language during the review cycle. The clinical team must be prepared to defend every word with data from the pivotal trial.
Dosage and AdministrationRecommended dose, schedule, and route. Dose modification guidelines for toxicity management — these must be clinically credible and supported by the dose modification data from the clinical trials. Dose modifications that were never actually used in trials are not credible label recommendations.
Warnings and PrecautionsEvery important identified safety risk must appear here with appropriate clinical guidance. FDA negotiates the language, severity (boxed warning vs warning vs precaution), and monitoring requirements. In oncology IO submissions, immune-mediated AEs generate extensive W&P language.
Adverse ReactionsAE rates from the safety population, typically presented as all AEs occurring in ≥10% of patients and all grade 3–4 AEs occurring in ≥2% of patients. The clinical team verifies that rates in the proposed label are consistent with the AE summary table in the CSR — any discrepancy will be found by the FDA reviewer.
Boxed WarningReserved for the most serious risks — those that may lead to death or serious injury. In oncology: hepatotoxicity, cardiotoxicity, embryo-fetal toxicity, severe immune reactions. A boxed warning is negotiated with FDA during the review cycle. The clinical team must prepare supporting data packages for any risk that FDA proposes for boxed warning status.
BLA vs NDA — key differences for oncologyBiologics
Manufacturing complexityBiological products are made in living cells — manufacturing variability is inherently higher than small molecule chemical synthesis. The BLA must demonstrate lot-to-lot consistency, characterization of the molecular entity (glycosylation, aggregation, immunogenicity), and comparability between clinical and commercial manufacturing processes. A change in the manufacturing process post-approval requires a comparability study — the clinical team reviews the clinical implications.
Immunogenicity assessmentAll biological products can induce anti-drug antibodies (ADA). The BLA must include a comprehensive immunogenicity package: ADA incidence, titer levels, clinical impact on PK, impact on efficacy, impact on safety (hypersensitivity reactions, infusion reactions). The clinical team reviews the ADA data for clinical relevance — high ADA rates with no clinical impact are different from high ADA rates with neutralizing effects on PK/PD.
Reference product (biosimilars)Once a BLA is approved, the product becomes a potential reference product for biosimilar applications. The originator BLA must establish the analytical characterization and clinical data package that will serve as the reference standard. This is relevant for post-approval lifecycle management.
CBER vs CDER jurisdictionMost oncology biologics (checkpoint inhibitors, therapeutic antibodies, ADCs) are reviewed by CDER's Office of Oncology Products despite being biological products. Cell and gene therapies (CAR-T, gene-edited cells) are reviewed by CBER. The reviewing division affects the regulatory science standards and the expertise of the review team.
IO / checkpoint inhibitor BLA — oncology-specific requirementsIO submissions
Biomarker strategy (PD-L1 / TMB)FDA requires that the BLA define the patient population by biomarker status if clinical benefit is shown to be biomarker-dependent. The PD-L1 assay must be co-developed and co-submitted as a companion diagnostic. The BLA must demonstrate analytical validation of the assay and clinical validation of the cut-off. Different assays (22C3, 28-8, SP263) are not interchangeable — the BLA specifies which assay is linked to the approved indication.
irAE safety packageThe irAE section of an IO BLA is one of the most scrutinized safety packages FDA reviews. Must include: incidence of all irAEs by system organ class and grade, time to onset and resolution, management (steroid dose and duration), re-challenge outcomes, deaths from irAEs. The proposed labeling W&P section for irAEs is typically the longest and most negotiated section of an IO label.
Combination IO submissionsDual checkpoint blockade (PD-1 + CTLA-4), IO + chemotherapy, IO + targeted therapy combinations require attribution of AEs to individual components. The BLA must include an attribution analysis — what AEs are driven by IO, what by the combination partner. Single-agent safety data for each component (where available) provides the comparator for this analysis.
REMS requirementsFDA may require a Risk Evaluation and Mitigation Strategy (REMS) for IO drugs with serious immune-mediated risks. The clinical team must assess whether the identified safety risks require REMS mitigation elements (medication guide, communication plan, elements to assure safe use). Early FDA discussion on REMS is recommended before submission.
ADC BLA — unique regulatory considerationsAntibody-drug conjugates
Antibody-drug conjugates (ADCs) are complex molecules — an antibody linked to a cytotoxic payload via a chemical linker. Their regulatory complexity reflects this three-component structure.
Three-component safety profileThe clinical team must characterize the safety contribution of each component: the antibody (target-mediated toxicities, immunogenicity), the linker (stability, premature payload release), and the payload (cytotoxic class effects — e.g., tubulin inhibitors cause neuropathy, DNA damaging agents cause myelosuppression). AEs that do not fit the expected profile of any single component may indicate linker instability releasing payload in off-target tissues.
Bystander effect safetyHigh drug-to-antibody ratio (DAR) ADCs with membrane-permeable payloads kill adjacent cells regardless of antigen expression (bystander effect). This is therapeutically useful but safety-relevant — off-target toxicity in antigen-negative tissues near the tumor. The BLA must characterize the relationship between DAR, payload permeability, and observed toxicities.
PK of total antibody vs free payloadADC PK is complex — three analytes are pharmacologically relevant: total antibody, conjugated antibody (ADC), and free payload. The BLA must report PK for all three and establish the relationship between each analyte and efficacy/safety endpoints. Free payload exposure is the primary driver of off-target toxicities.
Interstitial lung disease (ILD)ILD/pneumonitis is a class safety concern for many ADCs regardless of payload class. The BLA must include a dedicated ILD analysis: incidence, severity grading, time to onset, management, outcomes. In IO + ADC combinations, distinguishing immune-mediated pneumonitis from ADC-related ILD requires careful analysis.
Cell & gene therapy (CAR-T / gene editing) — clinical considerationsCBER reviewed
Single-dose paradigmMost CAR-T therapies are one-time infusions. Traditional repeat-dose safety and PK concepts do not apply. The BLA must characterize: in vivo cell expansion (Cmax), persistence (how long cells remain detectable), and the relationship between expansion kinetics and both efficacy (deeper expansion correlates with response) and safety (CRS, ICANS severity correlates with expansion magnitude).
CRS and ICANS safety packageCytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) are the defining safety challenges of CAR-T therapies. The BLA must include: incidence by ASTCT grade, time to onset, management (tocilizumab, corticosteroids, ICU requirements), resolution rates, and risk factors for severe CRS/ICANS. Grading must use the ASTCT 2019 consensus grading criteria.
Long-term follow-up (LTFU)FDA requires 15 years of long-term follow-up for integrating gene therapies (retroviral/lentiviral vectors) due to the theoretical risk of insertional oncogenesis. CAR-T therapies using integrating vectors carry this LTFU obligation. The clinical team must understand this commitment at the time of BLA submission — it is a post-marketing requirement, not optional.
Manufacturing failure and out-of-spec productCAR-T manufacturing can fail (insufficient T-cell expansion, contamination) or produce out-of-specification product. The BLA must address: what happens to patients when manufacturing fails, whether out-of-spec product was administered in clinical trials, and what clinical outcomes were observed in patients who received out-of-spec product.
Breakthrough Therapy Designation (BTD)Most intensive FDA collaboration
BTD is the most powerful oncology development program designation. It provides the most intensive FDA guidance during development — not just expedited review, but active FDA involvement in trial design, endpoint selection, and data interpretation.
Eligibility criteriaThe drug must be intended to treat a serious condition AND preliminary clinical evidence must indicate it may demonstrate substantial improvement over available therapy on a clinically significant endpoint. "Preliminary" means Phase 1 or early Phase 2 data. The clinical team prepares the BTD request — typically 10–20 pages of clinical evidence with the proposed improvement argument.
What BTD providesRolling review (NDA/BLA sections submitted as completed, not all at once). More frequent meetings with FDA. Cross-disciplinary meetings involving FDA clinical, statistical, and regulatory leads simultaneously. FDA commitment to provide timely advice on the development program. In oncology, BTD has been granted for drugs with ORR >30–40% in populations with no good alternatives.
Clinical team obligationsBTD creates an intensive collaboration — the clinical team must be prepared for more frequent FDA meetings (typically quarterly or more), must respond to FDA requests within tight timelines, and must engage productively in discussions about trial design and endpoint strategy. BTD does not guarantee approval — it guarantees more intensive guidance toward that goal.
Accelerated Approval — oncology's most important pathwaySurrogate endpoint basis
Accelerated Approval (AA) allows FDA to approve a drug based on a surrogate or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. In oncology, ORR is the most commonly used surrogate endpoint for AA. The confirmatory trial demonstrating clinical benefit (typically OS or PFS improvement vs control) is a post-marketing requirement.
Surrogate endpoints accepted in oncologyORR (for single-arm trials in settings with no good alternatives). PFS or DFS improvement vs control (for randomized trials when OS data is immature). Pathological complete response (pCR) in neoadjuvant settings. The clinical team must understand why FDA has determined the chosen surrogate is "reasonably likely to predict" OS — and be prepared to defend this linkage.
ORR threshold for AA in single-arm trialsNo fixed threshold — FDA evaluates ORR in the context of the disease setting (prior therapy burden, available alternatives, expected spontaneous response rate) and the durability of response (DoR). An ORR of 30% with durable responses in a refractory population is more compelling than 45% ORR with short responses in a first-line setting with available alternatives.
Confirmatory trial requirementsAs of the Omnibus Appropriations Act of 2023 (FDORA), FDA has strengthened requirements for confirmatory trials — they must be underway (not just planned) at the time of AA grant in most cases. The clinical team must have the confirmatory trial protocol finalized and enrollment ideally initiated before or concurrent with the AA submission.
Withdrawal riskIf the confirmatory trial fails to demonstrate clinical benefit, FDA can withdraw the accelerated approval (as it has done in numerous oncology cases). The clinical team must monitor the confirmatory trial actively — if interim data suggests the confirmatory trial is at risk of failure, early engagement with FDA is critical before the data becomes public.
Post-2023 landscape: FDA has significantly tightened AA standards following the 2022–2023 voluntary withdrawals of multiple oncology indications that failed confirmatory trials. The bar for ORR-based AA is now higher, and the confirmatory trial requirements are more stringent. The clinical team must account for this in early development planning.
Fast Track DesignationEarlier access to FDA
EligibilityDrug must treat a serious condition AND fill an unmet medical need. Lower bar than BTD — most oncology drugs qualify if they address a disease with inadequate current treatments. Can be requested at any time during development (pre-IND onward).
Key benefit — rolling reviewFast Track enables rolling review — the sponsor can submit completed sections of the NDA/BLA as they are ready, rather than submitting the complete package at once. This can reduce the time from data lock to approval by 3–6 months for programs where different modules complete at different times.
More frequent meetingsFast Track programs are eligible for more FDA meetings throughout development. Critically, Fast Track programs can request a pre-NDA/BLA meeting to align on submission content, format, and any unresolved scientific issues before the application is filed.
Priority Review Designation6-month review clock
What it doesReduces the FDA review clock from 12 months (standard review) to 6 months from the date of NDA/BLA filing acceptance. Priority Review does not change the content requirements — the same data package is needed. It accelerates FDA's internal review timeline, not the sponsor's development timeline.
Eligibility in oncologyDrug that treats a serious condition AND would provide a significant improvement in safety or effectiveness. In practice, most oncology submissions for serious malignancies with unmet need qualify. Priority Review is often granted alongside Fast Track or BTD but is a separate designation requested at the time of NDA/BLA submission.
PDUFA date implicationsFDA commits to completing the review by the PDUFA (action) date — 6 months from filing acceptance for Priority Review. The clinical team must be prepared to respond to FDA information requests (IR/IR) within very tight timelines during the review period — typically 24–72 hours for minor queries, 1–2 weeks for major requests.
Advisory Committee (AdCom) — what it is and why it mattersPublic scientific review
An Advisory Committee is a panel of external scientific and clinical experts convened by FDA to publicly evaluate a drug's benefit-risk and provide a non-binding recommendation to the agency. In oncology, the Oncologic Drugs Advisory Committee (ODAC) reviews submissions where FDA seeks external perspective on complex or controversial benefit-risk questions.
FDA is not required to follow the committee's recommendation but typically does in about 75% of cases. An AdCom is not a failed submission — it is a mechanism for FDA to demonstrate transparency on complex decisions. However, a negative AdCom vote significantly increases the probability of a Complete Response Letter (CRL) or approval with restrictive labeling.
FDA is not required to follow the committee's recommendation but typically does in about 75% of cases. An AdCom is not a failed submission — it is a mechanism for FDA to demonstrate transparency on complex decisions. However, a negative AdCom vote significantly increases the probability of a Complete Response Letter (CRL) or approval with restrictive labeling.
When FDA convenes ODACSignificant efficacy or safety uncertainty. Novel mechanism or target with limited clinical experience. Accelerated Approval applications where the surrogate-to-clinical benefit linkage is debated. Combination regimens with complex attribution. Post-marketing confirmatory trial failures requiring withdrawal decisions.
AdCom structurePublic meeting. FDA presents its benefit-risk analysis first. Sponsor presents clinical data. Public comments (patient advocates, KOLs, competing sponsors). Committee discussion. Vote on specific questions FDA poses. The vote is recorded and public. The entire meeting transcript becomes part of the public record.
Clinical team preparation for AdComHigh-stakes preparation
- Briefing document — the sponsor submits a briefing document to committee members before the meeting. This is typically 100–200 pages of clinical data presented in a narrative format. The clinical team writes the efficacy and safety sections. Every claim must be supported by data in the NDA/BLA. The briefing document becomes public 2 days before the meeting.
- FDA briefing document review — FDA simultaneously submits its own briefing document with its benefit-risk analysis. The clinical team must read the FDA briefing document immediately upon release and identify any areas of disagreement or misinterpretation that must be addressed in the presentation.
- Presentation development — the clinical team prepares a 60–90 minute presentation covering: disease background and unmet need, efficacy data (primary and key secondary endpoints), safety data, subgroup analyses, benefit-risk conclusion. Every slide must be defensible under expert questioning.
- Mock AdCom preparation — rehearsing responses to the hardest questions the committee is likely to ask. In oncology, these typically focus on: durability of response, OS data maturity, safety burden, patient population generalizability, and how the benefit-risk compares to existing alternatives.
- Patient advocate engagement — patient advocates frequently speak at AdComs and their perspective on unmet need carries significant weight. The clinical team coordinates with patient advocacy groups to ensure they have access to clinical data and can speak authentically about the disease burden and treatment options.
- Live data preparation — if any data has emerged since the NDA/BLA submission (updated OS, new safety events), the clinical team must assess whether this data strengthens or weakens the benefit-risk and prepare to present it at the AdCom.
PDUFA date and post-submission actionsApproval process
Filing acceptance (Day 74)FDA reviews the NDA/BLA for completeness and either accepts it for filing (confirming the PDUFA date) or issues a Refuse to File (RTF) letter identifying deficiencies. The clinical team reviews the filing acceptance letter for any FDA comments on the content — these foreshadow the review priorities.
Information requests (IR)During the review cycle, FDA issues Information Requests (IRs) for additional data, clarifications, or analyses not included in the submission. The clinical team must respond to IRs within the FDA-specified timeframe (typically 1–4 weeks). IR responses that are incomplete or evasive damage FDA's confidence in the submission team.
Complete Response Letter (CRL)Issued when FDA determines the application is not approvable in its current form. The CRL identifies all deficiencies that must be addressed before approval. The clinical team analyzes the CRL to determine: which deficiencies can be addressed with existing data vs which require new clinical studies. New clinical studies in oncology typically add 2–5 years to approval timelines.
Approval actionWhen FDA approves the application, it issues an approval letter, final prescribing information, and any post-marketing commitment letters. The clinical team reviews the final approved label against the proposed label — any FDA-imposed changes to Indications, Warnings, or Dosing require immediate communication to the field and to ongoing clinical trials using the drug.
Post-marketing commitments (PMC/PMR)Post-marketing commitments (voluntary) and post-marketing requirements (mandatory) are issued with every approval. In oncology AA, the confirmatory trial is a PMR. The clinical team is responsible for tracking PMC/PMR completion against FDA-agreed milestones and for submitting annual status reports.
EMA oncology submissions — key differences from FDAEuropean pathway
Marketing Authorization Application (MAA)The EMA equivalent of NDA/BLA. Submitted to EMA in eCTD format, identical structure to FDA submissions (both use ICH CTD). Reviewed by the Committee for Medicinal Products for Human Use (CHMP) with a designated rapporteur and co-rapporteur. Review clock: 210 days (active review days, excluding clock stops).
Conditional Marketing Authorization (CMA)EMA's equivalent of FDA Accelerated Approval. Granted when benefit-risk is positive but comprehensive data is not yet available. Requires annual renewal until the confirmatory data is submitted. The clinical team must fulfill post-authorization measures (PAMs) as conditions of the CMA — similar to FDA's PMRs.
PRIME designationPriority Medicines designation — EMA's equivalent of FDA Breakthrough Therapy. Provides early and enhanced scientific support. Key difference: PRIME offers a "kick-off" meeting with EMA very early in development to align on the regulatory strategy, accelerating the path to MAA.
Scientific AdviceEMA provides formal Scientific Advice during development — the clinical team can ask specific questions about trial design, endpoints, and data package requirements. Scientific Advice responses are not binding but carry significant regulatory weight. Divergence from EMA Scientific Advice without justification generates CHMP questions during MAA review.
EU HTA — HERA RegulationSince January 2025, the EU HTA Regulation requires joint clinical assessment (JCA) by the HERA body for new oncology drugs at the time of MAA. The clinical team must prepare a product-specific submission for HTA that addresses: added therapeutic benefit vs comparators, which may differ from FDA's efficacy framing. The comparator chosen for HTA analysis must reflect the European standard of care.
Pediatric Investigation Plan (PIP)Required for all new oncology drugs submitted to EMA. A PIP must be agreed with the Pediatric Committee (PDCO) before the MAA is filed. In oncology where adult and pediatric biology may differ (different tumor biology, different dosing), the PIP strategy requires clinical justification. A PIP waiver can be requested if the condition does not occur in children.
FDA vs EMA — key clinical differences in oncologyParallel submissions
Single-arm trial acceptanceFDA is generally more willing to accept single-arm ORR data for initial approval in oncology than EMA. EMA typically prefers randomized data, even for rare oncology indications. For drugs seeking both US and EU approval from a single pivotal trial, this creates tension in trial design strategy.
OS maturity requirementsEMA typically requires more mature OS data than FDA at the time of initial submission. A PFS-based approval that is acceptable to FDA may require a longer follow-up commitment for EMA. The clinical team managing parallel submissions must plan for this difference in the development timeline.
Comparator standardsFDA evaluates a drug against "available therapy" in the US. EMA evaluates against the EU standard of care, which may differ substantially. A drug showing improvement over chemotherapy in a setting where the EU standard of care is already a targeted therapy faces a higher comparative bar at EMA than at FDA.
Label negotiationsFDA and EMA approved labels for the same drug can differ significantly in their Indications (EU: biomarker population may be broader or narrower), Warnings (EU tends toward more precautionary language), and Dosing recommendations. The clinical team must manage both label negotiations simultaneously during parallel reviews.
Submission readiness checklist — clinical team
IND submission checklistBefore first patient
- Investigator's Brochure complete, reviewed by medical team, and version-controlled
- Phase 1 protocol: starting dose justified by preclinical data (NOAEL/HNSTD calculation documented), escalation schema specified, DLT definition comprehensive and clinically actionable
- Informed consent: all known preclinical risks translated to human terms, investigational nature clearly stated, alternative treatments described
- SAE reporting procedures in place: responsible party identified, 7-day and 15-day clock tracking established, expectedness assessment process documented
- Form FDA 1572 completed for all investigators at all planned sites
- IND annual report schedule established from Day 1 of IND receipt
NDA / BLA pre-submission checklistBefore filing
- Clinical Overview (2.5) written, reviewed, and clinically defensible — every claim has a supporting data reference
- All pivotal trial CSRs complete per ICH E3 — efficacy and safety sections reviewed by medical team, not just biostatistics
- Integrated Safety Summary (ISS): deaths analysis complete, Hy's Law analysis complete, QT/QTc analysis complete, special populations addressed
- Integrated Efficacy Summary (ISE): primary endpoint analysis, key secondary endpoints, subgroup analyses — all pre-specified in SAP
- Proposed prescribing information reviewed: Indications language evidence-based, Warnings supported by safety data, AE rates consistent with CSR tables, dosing modifications clinically validated
- T&L package complete: all tables internally consistent, all listings traceable, no unexplained numerical discrepancies between any two documents
- Biomarker/CDx strategy documented if applicable: assay validated, cut-off pre-specified, population definition consistent throughout all sections
- Post-marketing commitments identified and agreed internally: confirmatory trial protocol ready if Accelerated Approval pathway
- Pre-NDA/BLA meeting with FDA completed (if Fast Track): all outstanding issues documented and addressed in the submission
- REMS assessment completed: if required, REMS strategy developed and ready for FDA negotiation
During FDA review — clinical team obligationsActive review period
- IR response team assembled: clinical lead, biostatistics lead, regulatory affairs — available to respond within 24–72h for urgent requests
- FDA briefing document (when AdCom convened) read within 2 hours of public release — discrepancies with sponsor analysis identified and addressed in presentation
- Any new safety data emerging during review period assessed: does it change the benefit-risk? Does it require proactive FDA communication before the PDUFA date?
- Label negotiation tracker maintained: every FDA-proposed label change documented with sponsor response (accept / negotiate / reject with rationale)
- Post-approval launch readiness: field medical teams briefed on approved label, ongoing trial amendments if label changes affect eligibility criteria